Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunogen Inc (NQ: IMGN )

14.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71
Open 14.63
Bid (Size) 14.63 (3)
Ask (Size) 15.50 (2)
Prev. Close 14.63
Today's Range 14.63 - 14.63
52wk Range 3.605 - 20.69
Shares Outstanding 248,943,426
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire

Performance

YTD
+206.71%
+206.71%
1 Month
-5.86%
-5.86%
3 Month
-22.67%
-22.67%
6 Month
+283.99%
+283.99%
1 Year
+226.56%
+226.56%

More News

Read More
These 8 Stocks Are Outperforming Nvidia In 2023
Via Investor's Business Daily
10 Analysts Have This to Say About Immunogen
Via Benzinga
Analyst Ratings for Immunogen
Via Benzinga
BMO Capital Maintains Outperform Rating for Immunogen: Here's What You Need To Know
Via Benzinga
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
From ImmunoGen, Inc.
Via Business Wire
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
Via Benzinga
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
From ImmunoGen, Inc.
Via Business Wire
5 Meme Stocks to Sell Immediately, According to AI
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
Via InvestorPlace
How To Invest In The Healthcare Sector
Via Talk Markets
7 A-Rated Biotech Stocks for Your August Buy List
Via InvestorPlace
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Outperforms Q2 Revenue Expectations Bolstered By Strong Elahere Sales
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
From ImmunoGen, Inc.
Via Business Wire
Earnings Scheduled For July 31, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.